EMA Moves To Ensure ‘Smooth’ Evaluation Of Drug Approval Dossiers
Complex Cases May Still Require Tailored Meeting
Executive Summary
Drug sponsors seeking centralized EU marketing authorizations now have the opportunity to have simpler pre-submission “interactions” with the European Medicines Agency six months before the submission to help avoid complications down the line. Full meetings may still be appropriate for complex issues such as requests for accelerated assessment or conditional approval.
You may also be interested in...
Pandemic Treaty Could Have IP & Other Implications For Pharma
Equitable access to pandemic medicines and vaccines will be at the core of the WHO’s future global pandemic treaty. Exactly what this will mean for the pharmaceutical industry remains to be seen, but it is likely that companies wanting access to virus samples and other materials will need to agree to benefit sharing in the form of IP and technology transfer.
‘We Need Help,’ Says EMA Chief Amid COVID-19 & Burgeoning Workload
COVID-19, resource constraints and a forthcoming expansion of its responsibilities are piling the pressure on the EU regulator.
How To Avoid Regulatory Mistakes: Experts Put To The Test
Target product profiles, database locks, infarct size as a surrogate endpoint, and changes in the manufacturing process featured in a session of this year’s TOPRA Symposium on dealing with tricky regulatory questions.